Rakuten Medical’s Illuminox™
Rakuten Medical’s Illuminox™ is a proprietary, anti-cancer treatment platform that is comprised of drug, device and other related technologies. Transient excitation of the drug, including monoclonal antibodies conjugated to proprietary light-excitable dyes, with non-thermal light is believed to result in anti-cancer activity, which is mediated by biophysical processes that may compromise the membrane integrity of cells. The requirement of targeted binding of the drug to a specific antigen on the cell surface, and subsequent illumination, is believed to result in rapid and selective cell killing and tumor necrosis with minimal effects on surrounding normal tissue. It may also lead to the systemic induction of innate and adaptive immunity. Rakuten Medical’s Illuminox is based upon the photoimmunotherapy treatment platform developed at the National Institutes of Health (NIH) and licensed exclusively to Rakuten Medical for commercialization.
Rakuten Medical’s Illuminox is the platform used for the development of specific therapies using a combination of drug, device and other technologies. None of these therapies based on this platform have been approved by any regulatory authority. Rakuten Medical’s Illuminox platform is not a drug nor device on its own. The Illuminox name is not the brand name of a drug nor device.